Lisata Therapeutics (NASDAQ:LSTA) Receives Buy Rating from HC Wainwright

Lisata Therapeutics (NASDAQ:LSTA)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $15.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 410.20% from the stock’s previous close.

Lisata Therapeutics Stock Up 6.9 %

Shares of LSTA opened at $2.94 on Thursday. Lisata Therapeutics has a fifty-two week low of $2.05 and a fifty-two week high of $3.83. The company has a market cap of $24.67 million, a P/E ratio of -1.17 and a beta of 1.22. The firm’s 50 day moving average price is $2.94 and its 200 day moving average price is $3.09.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.16. During the same quarter in the previous year, the company earned ($0.65) earnings per share. Research analysts forecast that Lisata Therapeutics will post -2.84 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP grew its position in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,336 shares of the company’s stock after acquiring an additional 5,639 shares during the period. Dimensional Fund Advisors LP owned about 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent quarter. 8.94% of the stock is owned by institutional investors.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.